Breaking News Instant updates and real-time market news.

WYNN

Wynn Resorts

$181.24

1.66 (0.92%)

, MGM

MGM Resorts

$35.57

0.64 (1.83%)

08:44
04/06/18
04/06
08:44
04/06/18
08:44

On The Fly: Pre-market Movers

HIGHER: Wynn Resorts (WYNN), up 2% after The New York Post reported, citing sources, that MGM Resorts (MGM) has expressed interest in acquiring its rival casino operator... Crispr Therapeutics (CRSP), up 3% after Goldman Sachs initiated the stock with a Buy rating and $86 price target. UP AFTER EARNINGS: Greenbrier (GBX), up 4.5%. LOWER: Merck (MRK), down 1% after reporting that the Phase 3 ECHO-301/KEYNOTE-252 study evaluating Incyte's (INCY) epacadostat in combination with Merck's Keytruda in patients with unresectable or metastatic melanoma did not meet the primary endpoint of improving progression-free survival compared to Keytruda monotherapy. Shares of Incyte are down 22% following the news... Codexis (CDXS), down 10% after a 3.75M share spot secondary offering priced at $9.25... New Media (NEWM), down 7% after a 6M share spot secondary priced at $16.50... Sunrun (RUN), down 7% after BofA Merrill Lynch downgraded the stock two notches to Underperform from Buy... Xilinx (XLNX), down 4% after JPMorgan downgraded the stock to Underweight.

WYNN

Wynn Resorts

$181.24

1.66 (0.92%)

MGM

MGM Resorts

$35.57

0.64 (1.83%)

MRK

Merck

$54.53

-0.01 (-0.02%)

INCY

Incyte

$83.07

-0.91 (-1.08%)

GBX

Greenbrier

$49.30

1.4 (2.92%)

RUN

Sunrun

$9.94

0.12 (1.22%)

XLNX

Xilinx

$70.70

-0.44 (-0.62%)

CDXS

Codexis

$10.70

-0.1 (-0.93%)

CRSP

Crispr Therapeutics

$42.67

-1.48 (-3.35%)

NEWM

New Media

$17.41

0.06 (0.35%)

  • 06

    Apr

  • 06

    Apr

  • 09

    Apr

  • 14

    Apr

  • 23

    Apr

  • 23

    Apr

  • 24

    Apr

  • 26

    Apr

  • 01

    May

  • 29

    May

  • 12

    Jun

  • 23

    Oct

  • 06

    Apr

  • 06

    Apr

WYNN Wynn Resorts
$181.24

1.66 (0.92%)

03/23/18
03/23/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) and Wynn Macau (WYNMF) were upgraded to Buy from Hold at Union Gaming. 2. Cisco (CSCO) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Rod Hall saying as market volatility increases, Cisco provides a "relatively defensive" name in the sector. 3. General Mills (GIS) upgraded to Positive from Neutral at Susquehanna. 4. MPLX (MPLX) upgraded to Overweight from Equal Weight and Dominion Midstream (DM) upgraded to Equal Weight from Underweight at Morgan Stanley. 5. KB Home (KBH) upgraded to Outperform from Market Perform at Wells Fargo with analyst Stephen East saying the shares have fallen 25% since January 11, the worst in the group, while estimates "must rise." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/27/18
JPMS
03/27/18
NO CHANGE
Target $214
JPMS
Overweight
Wynn Resorts price target raised to $214 from $196 at JPMorgan
JPMorgan analyst Joseph Greff raised his price target for Wynn Resorts to $214 after increasing his 2018 and 2019 Macau property level EBITDA estimates by 3%. The analyst sees "continued healthy growth" in Macau and Wynn-specific premium mass momentum. Greff sees an "increasingly favorable" risk/reward on shares of Wynn Resorts following the "recent risk-reducing events" over the past month. He keeps an Overweight rating on the name.
04/02/18
ROTH
04/02/18
UPGRADE
Target $206
ROTH
Buy
Wynn Resorts upgraded to Buy from Neutral at Roth Capital
Roth Capital analyst David Bain upgraded Wynn Resorts to Buy from Neutral as he views regulatory and other risks as diminished, with Massachusetts likely remaining as the largest one still outstanding. While the analyst does not believe the "Steve Wynn stock multiple premium" will return, fundamental underpinnings are too strong for shares to not retrace at least closer to historical stock multiple averages in the near-to-intermediate term. Bain also raised his price target on the shares to $206 from $170.
04/02/18
04/02/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tesla (TSLA) upgraded to Hold from Underperform at Jefferies with analyst Philippe Houchois saying Tesla shares are down 32% from their September 2017 peak and he sees a "high probability" that management and the board, when releasing first quarter unit data this week, take "more drastic action" on guidance and funding to "restore credibility." 2. Allstate (ALL) upgraded to Market Perform from Underperform at Keefe Bruyette with analyst Meyer Shields expecting strong first quarter results from the company. 3. Discovery (DISCA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Marci Ryvicker saying she believes the stock offers a "compelling" risk/reward profile at current share levels. 4. Darden (DRI) was upgraded to Outperform from Sector Perform at RBC Capital and to Outperform from Market Perform at Raymond James. 5. Wynn Resorts (WYNN) upgraded to Buy from Neutral at Roth Capital with analyst David Bain saying he views regulatory and other risks as diminished, with Massachusetts likely remaining as the largest one still outstanding. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MGM MGM Resorts
$35.57

0.64 (1.83%)

03/08/18
STFL
03/08/18
NO CHANGE
STFL
Stifel returns from Macau trip with 'much more positive' view for 2018
Stifel analyst Steven Wieczynski said that after meeting with property managements and industry contacts in Macau recently he came back with a "much more positive/constructive view for 2018" than he was previously forecasting. It was clear that operators were "thrilled" with how the Chinese New Year holiday played out and demand post-CNY had continued to be strong, especially on the VIP side, Wieczynski tells investors. He maintains his Buy rating on Las Vegas Sands (LVS) and Hold ratings on MGM Resorts (MGM) and Wynn Resorts (WYNN). Melco Resorts (MLCO) is another publicly traded company in the Macau gaming space.
04/03/18
BOFA
04/03/18
NO CHANGE
BOFA
BofA/Merrill's Top 10 US Ideas for Q2 2018
BofA/Merrill introduced its Top 10 Ideas for Q2 2018. They are Buy rated Abbott (ABT), ADP (ADP),Coca-Cola European Partners (CCE), Discovery (DISCA), Dover (DOV), Lowe's (LOW), MGM Resorts (MGM), and Qualcomm (QCOM), and Underperform rated Ralph Lauren (RL) and BlackBerry (BB).
01/18/18
JEFF
01/18/18
INITIATION
Target $43
JEFF
Buy
MGM Resorts initiated with a Buy at Jefferies
Jefferies analyst David Katz started MGM Resorts (MGM) with a Buy rating and $43 price target. The analyst says the Cotai opening in the near term and positive capital deployment trump concerns over challenging Las Vegas comparisons. Katz initiated 11 Gaming names after today's close, naming Wynn Resorts (WYNN), Eldorado Resorts (ERI) and Penn National (PENN) his top picks.
03/15/18
MSCO
03/15/18
NO CHANGE
MSCO
Las Vegas Sands, Wynn Resorts targets raised at Morgan Stanley after Macau trip
After visiting Macau last week, Morgan Stanley analyst Thomas Allen raised his 2018/2019 EBITDA forecast for Las Vegas Sands by 1%, citing strong visitation growth over Chinese New Year, less MGM (MGM) Cotai cannibalization, and less renovation disruption at Cotai Central, all of which make him lower his projection for Las Vegas' market share decline to only 0.4% in loss versus his prior view of a 1% share loss. While it appears the new MGM Cotai has attracted a lot of visitors since opening, Allen believes a mixture of service issues and low hold will impact near-term results. For Wynn Resorts (WYNN), Allen raised his 2018/2019 EBITDA view by 4%/2% to reflect stronger results in both Macau and Vegas. Allen increased his price target on Las Vegas Sands shares to $82 from $81, upped his Wynn target to $194 from $193 and keeps a $40 price target on MGM Resorts.
MRK Merck
$54.53

-0.01 (-0.02%)

04/05/18
LEHM
04/05/18
NO CHANGE
LEHM
Barclays upgrades Merck, downgrades Biogen and Pfizer in sector reassessment
Barclays analyst Geoff Meacham made some rating changes while reassessing the Biopharmaceutical sector. Biopharma sentiment has been negative since the start of 2018, despite a modest pick-up in deals and diminished rhetoric on drug pricing, Meacham tells investors in a research note titled "U.S. Biopharmaceuticals: Where to from here?" The analyst believes "more transformative" acquisitions, "clean" Phase 3 wins, and even a relatively strong Q1 earnings season could help "re-rate the sector" and get investors more engaged in the group. Ahead of the Q1 earnings season, Meacham upgraded Merck (MRK) to Overweight from Equal Weight and downgraded to Equal Weight from Overweight shares of Biogen (BIIB), Pfizer (PFE), Biohaven Pharmaceutical (BHVN) and Myovant Sciences (MYOV). The analyst also lowered his price target for Equal Weight-rated AbbVie (ABBV) to $102 from $120, for Equal Weight-rated Amgen (AMGN) to $180 from $180, for Overweight-rated Prothena (PRTA) to $50 from $70 and for Overweight-rated Incyte (INCY) to $135 from $165.
04/05/18
LEHM
04/05/18
UPGRADE
Target $64
LEHM
Overweight
Merck upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Geoffrey Meacham upgraded Merck to Overweight and raised his price target for the shares to $64 from $62. The analyst believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data.
04/05/18
04/05/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Merck (MRK) upgraded to Overweight from Equal Weight at Barclays with analyst Geoffrey Meacham saying he believes the company will continue to take share in first-line lung cancer, driven by positive KN-189 and KN-042 data. 2. Acuity Brands (AYI) upgraded to Outperform from Market Perform at JMP Securities with analyst Joseph Osha saying he believes the stock is finally trading at a "reasonable valuation based on reasonable expectations." 3. AMD (AMD) upgraded to Buy from Hold at Stifel with analyst Kevin Cassidy citing valuation and the company's margin expansion potential. 4. Tiffany (TIF) upgraded to Buy from Hold at Loop Capital with analyst Laura Champine saying her initial meeting with the company's new CEO Alessandro Bogliogo added to her confidence. 5. Citi (C) and Wells Fargo (WFC) were upgraded to Buy from Neutral at UBS. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/12/18
03/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Time Warner (TWX) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying while he expects the takeover by AT&T (T) to receive regulatory approval, he believes the current environment would make Time Warner's assets "highly attractive" to other media companies and Internet-based competitors were the deal to be blocked. 2. Carlyle Group (CG) and Apollo Global (APO) were upgraded to Buy from Neutral at Citi. 3. Merck (MRK) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez saying Keytruda will continue to dominate the first-line non-small cell lung cancer market. 4. SAP (SAP) upgraded to Outperform from In Line at Evercore ISI with analyst Stewart Materne III saying that he believes the risk/reward is more attractive at current levels following the stock's 6% pullback. 5. Aratana Therapeutics (PETX) upgraded to Buy on valuation at CL King with the firm citing favorable risk/reward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
INCY Incyte
$83.07

-0.91 (-1.08%)

01/22/18
OPCO
01/22/18
NO CHANGE
Target $110
OPCO
Perform
Incyte price target lowered to $110 from $120 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte to $110 from $120 as he now sees a higher hurdle in NSCLC for epa and consequently lower probability of success than previously. The analyst reiterates a Perform rating on the shares.
01/16/18
MZHO
01/16/18
DOWNGRADE
Target $23
MZHO
Neutral
Concert Pharmaceuticals downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Concert Pharmaceuticals (CNCE) to Neutral with a $23 price target after the Patent Trial and Appeal Board did not grant the company a Post Grant Review in the ongoing Patent '355 dispute with Incyte Pharma (INCY). While the firm believes this development has no implications for the ultimate outcome of the trial, it does mean the litigation overhang will remain in the foreseeable future. Further, Mizuho sees the stock as fairly valued.
02/15/18
BMOC
02/15/18
NO CHANGE
BMOC
Incyte risk/reward is favorable, says BMO Capital
GBX Greenbrier
$49.30

1.4 (2.92%)

01/04/18
GHSC
01/04/18
INITIATION
Target $65
GHSC
Buy
Greenbrier initiated with a Buy at Seaport Global
Seaport Global analyst Williard Milby initiated Greenbrier with a Buy and $65 price target. Milby believes Greenbrier is well positioned domestically, and resent international expansions should impact the bottom-line immediately, with solid potential for long-term growth.
07/17/17
STFL
07/17/17
UPGRADE
STFL
Buy
Greenbrier upgraded on recent deals, results at Stifel
As noted earlier, Stifel upgraded Greenbrier to Buy from Hold. Analyst Michael J. Baudendistel,says that the market is underestimating the benefits of the company's deal with MUL and its international expansion. Additionally, he believes that the "longer term implications" of the results it reported last month were "exceedingly positive," while its "execution has been impressive" recently. Target to $51 from $48.
07/16/17
STFL
07/16/17
UPGRADE
STFL
Buy
Greenbrier upgraded to Buy from Hold at Stifel
07/17/17
07/17/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Rentals (URI) upgraded to Outperform from Sector Perform at RBC Capital with analyst Seth Weber citing consolidation within the rental space and positive comments by rental company Sunbelt as two reasons for the upgrade. 2. Fifth Street Finance (FSC) upgraded to Outperform from Market Perform at JMP Securities with analyst Christopher York saying that the deal under which Oaktree (OAK) will become Fifth Street's investment adviser will improve both companies' corporate governance and lower Fifth Street's costs. 3. CACI (CACI) upgraded to Buy from Hold at Jefferies with analyst Sheila Kahyaoglu saying she views the company's portfolio geared towards defense solutions as "compelling" and she likes its "aggressive" capital deployment strategy. 4. Greenbrier (GBX) upgraded to Buy from Hold at Stifel with analyst Michael Baudendistel saying that the market is underestimating the benefits of the company's deal with Mitsubishi UFJ Lease & Finance and its international expansion. 5. Bottomline Technologies (EPAY) upgraded to Outperform from Market Perform at Raymond James with analyst Wayne Johnson saying he thinks the company is entering a period of high margins and more linear revenue growth and is excited about positive operating leverage from rising sales momentum and contracts that have already been expensed over a fixed cost infrastructure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RUN Sunrun
$9.94

0.12 (1.22%)

04/05/18
ROTH
04/05/18
NO CHANGE
ROTH
Solar 'doges bullet' as inverters/cells/modules sidestep 301 tariffs, says Roth Capital
Roth Capital analyst Philip Shen notes that inverters, solar cells, and solar modules were not on the 301 product list released on the USTR website providing which Chinese imports will be subject to 25% tariffs. A 301 tariff that increases module or inverter costs in the U.S. could have served as another dampener of U.S. solar demand, he contends, adding that the lack of impact represents an overall positive for the industry and positive for most in his coverage universe, including Canadian Solar (CSIQ), Enphase Energy (ENPH), First Solar (FSLR), Hanwah Q CELLS (HQCL), JinkoSolar (JKS), Sunrun (RUN), SolarEdge (SEDG), ReneSola (SOL), Sunworks (SUNW), and Yingli Green Energy (YGE).
04/06/18
BOFA
04/06/18
DOWNGRADE
BOFA
Underperform
Sunrun downgraded to Underperform from Buy at BofA/Merrill
04/06/18
04/06/18
DOWNGRADE

Underperform
Sunrun downgraded to Underperform following recent run in shares at BofA/Merrill
As previously reported, BofA/Merrill downgraded Sunrun two notches to Underperform from Buy and raised its price target to $10 from $9. Analyst Julien Dumoulin-Smith views upside as limited following the 66% run in shares year-to-date and is cautious given execution risk and growth expectations already reflected in shares.
04/06/18
GSCO
04/06/18
NO CHANGE
Target $12
GSCO
Buy
Sunrun price target raised to $12 at Goldman Sachs on improving cash flow
Goldman Sachs analyst Brian Lee raised his price target on Sunrun to $12 from $10 and kept his Buy rating, saying the company's "improving cash flow profile appears to be sustainable and growth-oriented". Lee adds that the performance runs counter to the broader perception on residential solar power businesses and expects continued outperformance in the Sunrun stock amid positive cash generation.
XLNX Xilinx
$70.70

-0.44 (-0.62%)

02/22/18
RBCM
02/22/18
NO CHANGE
Target $325
RBCM
Top Pick
RBC finds takeover targets for Broadcom should Qualcomm deal fail
RBC Capital analyst Amit Daryanani finds it prudent to think about other takeover options for Broadcom (AVGO) should its attempt to acquire Qualcomm (QCOM) fail. Broadcom is in a "unique position" as it generates $9B-$10B of free cash flow annually, has balance sheet that is "almost net debt neutral" and a management team "that has impeccable history in integrating assets," Daryanani tells investors in a research note titled "If not QCOM, Who Is Next?" The analyst sees potential targets in Xilinx (XLNX), Analog Devices (ADI), Maxim Integrated (MXIM), Marvell Technology (MRVL) and Microsemi (MSCC). Daryanani keeps a Top Pick rating on Broadcom with a $325 price target. He believes the company has the ability to sustain double-digit growth with or without Qualcomm.
01/25/18
RHCO
01/25/18
NO CHANGE
Target $79
RHCO
Hold
Xilinx price target raised to $79 from $69 at SunTrust
SunTrust analyst William Stein raised his price target on Xilinx to $79 and kept his Hold rating after Q3 earnings. Stein notes that while revenues excluding Comms and Data Center sales continued to outperform amid 20% annual growth in automotive and the emerging exposure to cryptocurrencies, Comms and Data end market underperformed again and may remain challenging until 5G fully launches around 2020.
03/13/18
KEYB
03/13/18
NO CHANGE
KEYB
Broadcom could look at Micron next with Qualcomm blocked, says KeyBanc
President Trump's order to block Broadcom's (AVGO) proposed takeover of Qualcomm (QCOM) also likely blocks the possibility of the company trying to acquire any other player with any military/defense exposure, such as Xilinx (XLNX), KeyBanc analyst John Vinh tells investors. However, he expects Broadcom to remain acquisitive and thinks Micron (MU) could be another potential target, citing a lack of security concerns and Broadcom's previous attempts to bid for Toshiba (TOSBF), he noted. Vinh reiterates his Overweight rating and $320 price target on Broadcom, adding that he sees the executive order as a "slight positive," since it removes a near-term distraction and overhang.
04/06/18
JPMS
04/06/18
DOWNGRADE
Target $68
JPMS
Underweight
Xilinx downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Harlan Sur downgraded Xilinx to Underweight and cut his price target for the shares to $68 from $73. The analyst believes multiple compression is likely with basestation deployment in China likely to decline in 2018. Further, the analyst believes expectations for 5G are high.
CDXS Codexis
$10.70

-0.1 (-0.93%)

03/09/18
JEFF
03/09/18
NO CHANGE
Target $11
JEFF
Buy
Codexis remains a top small-cap growth idea at Jefferies
Jefferies analyst Brandon Couillard says Codexis is entering 2018 with diversifying revenue streams and positive momentum on multiple fronts. The company's guide for over 20% growth does not factor another CodeEvolver deal, which consensus did include, Couillard tells investors in a research note. He thinks the market continues to underappreciate the company's therapeutic discovery opportunity and keeps a Buy rating on the shares with an $11 price target.
05/31/17
JEFF
05/31/17
INITIATION
Target $8
JEFF
Buy
Codexis initiated with a Buy at Jefferies
Jefferies analyst Brandon Couillard started Codexis with a Buy rating and $8 price target. The company is an expert in protein engineering and custom enzymes used in commercial manufacturing, Couillard tells investors in a research note. He views Codexis as an "under-appreciated small-cap growth idea."
10/13/17
CHLM
10/13/17
NO CHANGE
Target $7
CHLM
Buy
Market just beginning to recognize Codexis opportunity, says Craig-Hallum
Craig-Hallum analyst Matt Hewitt says Codexis (CDXS) has a "unique proprietary CodeEvolver protein engineering platform" that is being sought by large pharma names, citing yesterday's announcement of a partnership with Nestle (NSRGY). Hewitt says that despite the recent stock price appreciation, the increasing value of the company's development pipeline suggests the markets is just starting to recognize the opportunity. The analyst has a Buy rating and a $7 price target on the stock.
CRSP Crispr Therapeutics
$42.67

-1.48 (-3.35%)

04/06/18
GSCO
04/06/18
INITIATION
Target $86
GSCO
Buy
Crispr Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs started Crispr Therapeutics with a Buy rating and $86 price target.
03/09/18
RHCO
03/09/18
NO CHANGE
Target $65
RHCO
Buy
Crispr Therapeutics price target raised to $65 from $45 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Crispr Therapeutics to $65, citing the company's Q4 earnings beat along with the approval of one of its CTAs for beta thalassemia in Europe. Lawson adds that he has also added the company's allogeneic CAR T candidate to his model and recommends a Buy "ahead of potential first in human data this year".
03/09/18
PIPR
03/09/18
NO CHANGE
Target $67
PIPR
Overweight
Crispr Therapeutics price target raised to $67 from $39 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Crispr Therapeutics to $67 to reflect more value to the company's pipeline. The stock closed yesterday up 4% to $53.70. First-in-man Crisper data will be an important milestone, Tenthoff tells investors in a research note. He believes the company's cash of $362M is enough to conduct a CTX001 beta thalassemia study this year. First-in-man CTX001 data will serve as an important driver and set up potential "rapid approval" in beta-thal by 2020 and sickle cell disease by 2021 with "blockbuster" sales potential, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Crispr Therapeutics.
03/08/18
03/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyler Technologies (TYL) initiated with a Neutral at DA Davidson. 2. Interpace Diagnostics (IDXG) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with an Outperform at JMP Securities. 4. Quanta Capital Hldgs (QNTA) initiated with an Outperform at Northland. 5. Genocea (GNCA) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NEWM New Media
$17.41

0.06 (0.35%)

05/02/17
SPHN
05/02/17
UPGRADE
SPHN
Overweight
New Media upgraded to Overweight from Equal Weight at Stephens
Stephens analyst Kyle Evans upgraded New Media to Overweight from Equal Weight, citing its double-digit dividend yield.

TODAY'S FREE FLY STORIES

ANTM

Anthem

$238.81

13.73 (6.10%)

05:22
04/26/18
04/26
05:22
04/26/18
05:22
Upgrade
Anthem rating change  »

Anthem upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$159.69

0.03 (0.02%)

05:20
04/26/18
04/26
05:20
04/26/18
05:20
Recommendations
Facebook analyst commentary  »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERN

Erin Energy

$1.65

-0.825 (-33.33%)

05:18
04/26/18
04/26
05:18
04/26/18
05:18
Hot Stocks
Erin Energy files voluntary petitions under Chapter 11 to pursue reorganization »

Erin Energy and certain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$96.54

0.04 (0.04%)

05:16
04/26/18
04/26
05:16
04/26/18
05:16
Recommendations
Citrix analyst commentary  »

Citrix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 08

    May

  • 09

    May

AMD

AMD

$9.72

-0.37 (-3.67%)

05:13
04/26/18
04/26
05:13
04/26/18
05:13
Recommendations
AMD analyst commentary  »

AMD could see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EBAY

eBay

$40.98

-0.2 (-0.49%)

05:09
04/26/18
04/26
05:09
04/26/18
05:09
Recommendations
eBay analyst commentary  »

eBay GMV growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.71

-1.65 (-25.94%)

05:01
04/26/18
04/26
05:01
04/26/18
05:01
Downgrade
Trivago rating change  »

Trivago downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPR

HighPoint Resources

$6.65

0.14 (2.15%)

04:58
04/26/18
04/26
04:58
04/26/18
04:58
Initiation
HighPoint Resources initiated  »

HighPoint Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

AVY

Avery Dennison

$106.68

1.195 (1.13%)

04:57
04/26/18
04/26
04:57
04/26/18
04:57
Upgrade
Avery Dennison rating change  »

Avery Dennison upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/21 Jobless…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/25 Fed Balance…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

WYN

Wyndham

$117.67

1.83 (1.58%)

, LQ

La Quinta

$19.70

0.08 (0.41%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
La Quinta to host special shareholder meeting »

Special Shareholder…

WYN

Wyndham

$117.67

1.83 (1.58%)

LQ

La Quinta

$19.70

0.08 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Wholesale Inventories [Advance] M/M % hange to be reported at 08:30 »

March Wholesale…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

March International Trade…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/16 Money Supply…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/20 EIA Natural…

SMMT

Summit Therapeutics

$13.66

0.13 (0.96%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Summit Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

ABBV

AbbVie

$91.91

0.57 (0.62%)

, ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
American Academy of Neurology to hold annual meeting »

2018 Annual Meeting of…

ABBV

AbbVie

$91.91

0.57 (0.62%)

ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

ALXN

Alexion

$106.07

-0.37 (-0.35%)

AKCA

Akcea Therapeutics

$26.85

0.02 (0.07%)

RHHBY

Roche

TEVA

Teva

$17.27

-0.28 (-1.60%)

UBS

UBS

$16.78

-0.095 (-0.56%)

MDT

Medtronic

$79.47

0.12 (0.15%)

MCK

McKesson

$151.70

2.76 (1.85%)

NVTA

Invitae

$5.53

-0.15 (-2.64%)

IONS

Ionis Pharmaceuticals

$43.98

-1.35 (-2.98%)

IPXL

Impax

$19.25

-0.65 (-3.27%)

DNA

Bought by RHHBY

DGX

Quest Diagnostics

$101.17

1.42 (1.42%)

ESALY

Eisai

DEPO

Depomed

$6.66

-0.17 (-2.49%)

CPRX

Catalyst Pharmaceuticals

$2.64

0.04 (1.54%)

BSX

Boston Scientific

$29.44

1.01 (3.55%)

BMRN

BioMarin

$81.41

0.33 (0.41%)

MYL

Mylan

$38.93

-1.32 (-3.28%)

NBIX

Neurocrine

$78.13

-0.3 (-0.38%)

NVS

Novartis

$76.42

-0.58 (-0.75%)

PFE

Pfizer

$36.69

-0.36 (-0.97%)

RARX

RA Pharmaceuticals

$5.76

-0.2 (-3.36%)

SNY

Sanofi

$40.11

0.335 (0.84%)

SYK

Stryker

$165.44

0.77 (0.47%)

SUPN

Supernus

$47.30

0.55 (1.18%)

LLY

Eli Lilly

$81.17

1.08 (1.35%)

BAYRY

Bayer

AMGN

Amgen

$174.83

2.92 (1.70%)

ALNY

Alnylam

$94.35

-0.34 (-0.36%)

BIIB

Biogen

$269.47

7.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 16

    Jun

  • 06

    Jul

  • 11

    Aug

  • 12

    Sep

  • 05

    Oct

  • 20

    Oct

  • 13

    Nov

  • 28

    Jan

SCPH

scPharmaceuticals

$9.92

-0.1 (-1.00%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
scPharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    Jun

ALNA

Allena Pharmaceuticals

$14.77

0.845 (6.07%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RIO

Rio Tinto

$55.24

-0.44 (-0.79%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Rio Tinto management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/22 Bloomberg…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.